1. Home
  2. Management and Treatment of MDS
  3. Expert Video - How is higher-risk MDS treated?

Expert Video - How is higher-risk MDS treated?

MDS experts, Dr Alan List and Dr David Sallman, explain that the goals of therapy for patients with higher-risk myelodysplastic syndromes (MDS) are to improve symptoms, decrease the risk of leukemia, and improve survival. The primary treatment options for higher-risk MDS discussed are: hypomethylating agents (azacitidine and decitabine) and allogeneic stem cell transplant.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.

Other Modules:

Managing and Treating MDS-related Anemia

Managing and Treating MDS-related Anemia

Mutation-Driven Therapy in MDS

Mutation-Driven Therapy in MDS

Understanding MDS

Understanding Myelodysplastic Syndromes

Understanding MDS-related Anemia

Understanding MDS-related Anemia

Understanding Erythropoiesis

Understanding Erythropoiesis

Diagnosis of MDS

Diagnosis of MDS

Understanding Genetic Mutations in MDS

Understanding Genetic Mutations in MDS

Blood and Marrow Transplantation in MDS

Blood and Marrow Transplantation in MDS

Understanding Clinical Trials in MDS

Understanding Clinical Trials in MDS

Including Everyone in Clinical Trials for MDS

Including Everyone in Clinical Trials for MDS

Animation - Management and Treatment of MDS
Animation - Management and Treatment of MDS
Slide Show - Management and Treatment of MDS
Slide Show - Management and Treatment of MDS
Expert Videos
What are the treatment options for MDS?
1. What are the treatment options for MDS?
How is lower-risk MDS treated?
2. How is lower-risk MDS treated?
How is higher-risk MDS treated?
3. How is higher-risk MDS treated?
What is supportive care for MDS?
4. What is supportive care for MDS?
Are vitamin supplements beneficial for MDS treatment?
5. Are vitamin supplements beneficial for MDS treatment?
What are erythropoietin-stimulating agents (ESAs)?
6. What are erythropoietin-stimulating agents (ESAs)?
What is cytotoxic chemotherapy and when is it used for MDS?
7. What is cytotoxic chemotherapy and when is it used for MDS?
What is lenalidomide and when is it used for MDS?
8. What is lenalidomide and when is it used for MDS?
What are hypomethylating agents and when are they used for MDS?
9. What are hypomethylating agents and when are they used for MDS?
How long will MDS treatment be given?
10. How long will MDS treatment be given?
What is immunosuppressive therapy and when is it used for MDS?
11. What is immunosuppressive therapy and when is it used for MDS?
What other options are there if first-line MDS treatment doesn’t work?
12. What other options are there if first-line MDS treatment doesn’t work?
Patient Videos
David's story: How was your MDS initially treated?
13. David's story: How was your MDS initially treated?
 

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.